Your browser doesn't support javascript.
loading
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.
Naito, Yoichi; Mishima, Saori; Akagi, Kiwamu; Hayashi, Naomi; Hirasawa, Akira; Hishiki, Tomoro; Igarashi, Ataru; Ikeda, Masafumi; Kadowaki, Shigenori; Kajiyama, Hiroaki; Kato, Motohiro; Kenmotsu, Hirotsugu; Kodera, Yasuhiro; Komine, Keigo; Koyama, Takafumi; Maeda, Osamu; Miyachi, Mitsuru; Nishihara, Hiroshi; Nishiyama, Hiroyuki; Ohga, Shouichi; Okamoto, Wataru; Oki, Eiji; Ono, Shigeru; Sanada, Masashi; Sekine, Ikuo; Takano, Tadao; Tao, Kayoko; Terashima, Keita; Tsuchihara, Katsuya; Yatabe, Yasushi; Yoshino, Takayuki; Baba, Eishi.
Afiliación
  • Naito Y; National Cancer Center Hospital East, Kashiwa, Japan.
  • Mishima S; National Cancer Center Hospital East, Kashiwa, Japan.
  • Akagi K; Saitama Cancer Center, Saitama, Japan.
  • Hayashi N; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Hirasawa A; Okayama University, Okayama, Japan.
  • Hishiki T; Chiba University, Chiba, Japan.
  • Igarashi A; Yokohama City University School of Medicine, Yokohama, Japan.
  • Ikeda M; National Cancer Center Hospital East, Kashiwa, Japan.
  • Kadowaki S; Aichi Cancer Center, Aichi, Japan.
  • Kajiyama H; Nagoya University, Aichi, Japan.
  • Kato M; The University of Tokyo, Tokyo, Japan.
  • Kenmotsu H; Shizuoka Cancer Center, Shizuoka, Japan.
  • Kodera Y; Nagoya University Hospital, Aichi, Japan.
  • Komine K; Tohoku University, Miyagi, Japan.
  • Koyama T; National Cancer Center Hospital, Tokyo, Japan.
  • Maeda O; Nagoya University Hospital, Aichi, Japan.
  • Miyachi M; Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Nishihara H; Keio University, Tokyo, Japan.
  • Nishiyama H; Tsukuba University, Ibaraki, Japan.
  • Ohga S; Kyushu University, Fukuoka, Japan.
  • Okamoto W; Hiroshima University Hospital, Hiroshima, Japan.
  • Oki E; Kyushu University, Fukuoka, Japan.
  • Ono S; Jichi Medical University, Tochigi, Japan.
  • Sanada M; National Hospital Organization Nagoya Medical Center, Aichi, Japan.
  • Sekine I; Tsukuba University, Ibaraki, Japan.
  • Takano T; Tohoku University, Miyagi, Japan.
  • Tao K; National Cancer Center Hospital, Tokyo, Japan.
  • Terashima K; National Center for Child Health and Development, Tokyo, Japan.
  • Tsuchihara K; National Cancer Center Hospital East, Kashiwa, Japan.
  • Yatabe Y; National Cancer Center Hospital, Tokyo, Japan.
  • Yoshino T; National Cancer Center Hospital East, Kashiwa, Japan.
  • Baba E; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. baba.eishi.889@m.kyushu-u.ac.jp.
Int J Clin Oncol ; 28(7): 827-840, 2023 Jul.
Article en En | MEDLINE | ID: mdl-37212982
BACKGROUND: Clinical trials have reported the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors. The accumulated evidence of tumor-agnostic agent has made since TRK inhibitors were approved and used in clinical practice. Therefore, we have revised the 'Japan Society of Clinical Oncology (JSCO)/Japanese Society of Medical Oncology (JSMO)-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese Society of Pediatric Hematology/Oncology (JSPHO)'. METHODS: Clinical questions regarding medical care were formulated for patients with NTRK fusion-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by JSCO, JSMO, and JSPHO voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. RESULTS: The current guideline describes 3 clinical questions and 14 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors. CONCLUSION: The committee proposed 14 recommendations for performing NTRK testing properly to select patients who are likely to benefit from TRK inhibitors.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tropomiosina / Proteínas Tirosina Quinasas Receptoras / Neoplasias Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Adult / Child / Humans País/Región como asunto: Asia Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tropomiosina / Proteínas Tirosina Quinasas Receptoras / Neoplasias Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Adult / Child / Humans País/Región como asunto: Asia Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón